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Modulation of testosterone levels is a therapeutic approach for spinal and bulbar muscular atrophy (SBMA),
a polyglutamine disorder that affects the motor neurons. The article by Palazzolo et al. in this issue of Neuron
provides compelling evidence that the expression of insulin growth hormone is a potential therapeutic for
SBMA.Spinal and bulbar muscular atrophy
(SBMA), a rare neurodegenerative condi-
tion (Fischbeck, 1997), was first described
by William R. Kennedy in 1968 (Kennedy
et al., 1968), who recalled the first case
as being ‘‘an exciting patient.’’ Since this
first report, it took about two decades
to locate the genetic marker on the
proximal long arm of the X chromosome
(Fischbeck et al., 1986) and identify the
presence of CAG expansion within the
first exon of the androgen receptor (AR)
gene in SBMA (La Spada et al., 1991).
This cardinal genetic defect first discov-
ered for SBMA classifies it into the group
of polyglutamine (polyQ) neurodegenera-
tive disorders with the classical pheno-
typic features including anticipation of
disease onset associated with a threshold
of expanded CAG repeats, cytoplasmic/
nuclear inclusions, and mitochondrial
dysfunction. The unique character of the
individual proteins affected by the poly-
glutamine expansion reflects distinct
pathologies and symptoms for these
diseases. The pathophysiology for SBMA
consists of fasciculations, proximal mu-
scle weakness, and sensory atrophy with-
out affecting cognitive function, unlike
Huntington’s disease and spinocerebellar
ataxias (Kennedy et al., 1968; Sobue et al.,
1989; Sperfeld et al., 2002). Although
SBMAprogresses rather slowly, the prog-
nosis is poor due to complications associ-
ated with respiratory infection (Sobue,
2003). To date, available treatments limit
testosterone levels to prevent transloca-
tion of the mutant AR to the nucleus and
aggregate formation. This approachmight
partially prolong the lifespan of patients
and ameliorate some of the debilitating
symptoms of the condition. However,
side effects associated with infertility,
gynecomastia, and the inability of someandrogen antagonists (e.g., flutamide) to
effectively reverse SBMA phenotype limit
treatment options for this disorder.
What is our current understanding of
how mutant AR causes neurodegenera-
tion?Many questions remain unanswered
for the myriad nuclear and cellular abnor-
malities caused by polyQ diseases, but
AR has a known function as a steroid
hormone receptor and this has signifi-
cantly advanced our understanding of
the mechanism of neurodegeneration
causing this disease. In the SBMA field,
the ligand-dependant hypothesis is prev-
alent to model SBMA pathology. Upon
ligand binding, the AR, which contains
a nuclear localization signal, undergoes
a series of conformational changes and
translocates to the nucleus by means of
heat shock protein 90. Nuclear localiza-
tion of mutant AR in the presence of
androgens is required for SBMA (Katsuno
et al., 2002; Montie et al., 2009). Tran-
scriptional deregulation (e.g., inhibition
of cellular proteins including CBP protein)
and dysfunctional protein processing are
primarily responsible for formation of
nuclear inclusions (Ellerby et al., 1999;
McCampbell et al., 2000; Sopher et al.,
2004).
In this issue of Neuron, Palazzolo et al.
(2009) refine the ligand-dependent hy-
pothesis and provide a novel way to
correct aberrant signaling mediated by
mutant AR using insulin-like growth
factor-1 (IGF-1). IGF-1 is a widespread
classical hormone involved in cell growth
and in some cases brain plasticity. With a
series of elegant in vitro assays using
COS1 cells transfected with human
mutant AR65, the authors demonstrate
that phosphorylation of Akt at serine 473
is stimulated by the addition of IGF-1.
The activation of Akt decreases AR-medi-Neuron 6ated aggregation by 68%.AR aggregation
was dependent on activation of the PI3K/
Akt pathway and phosphorylation of AR
by Akt since PI3K inhibitor LY294002
blocked IGF-1-mediated reduction in
aggregation.
From these data, Palazzolo et al. (2009)
hypothesize that one of the mechanisms
in which IGF-1 exerts its beneficial effect
is through phosphorylation of Akt at serine
473 residue, and subsequently, AR at
serine 215 by Akt selectively in SBMA
muscle. To evaluate the potential benefit
of exogenous IGF-1 in vivo, SBMA mice
overexpressing human AR97Q were
crossed with mice that overexpress a
muscle-specific isoform of IGF-1 selec-
tively in skeletal muscle. Akt was acti-
vated and phosphorylation of AR at serine
215 occurs in these mice. Furthermore,
IGF-1 rescues behavioral and histopatho-
logical abnormalities, delays disease
onset, and prolongs the lifespan of
SBMA mice. IGF-1 also attenuates the
morphological and molecular signs of
myopathic and neurogenic muscle
pathology and increases motor neuron
survival.
Based on a series of gain- and loss-of-
function experiments, Palazzolo et al.
(2009) clearly demonstrate that IGF-1
promotes clearance ofmutant AR through
the ubiquitin-proteasome pathway in
a phosphorylation-dependant manner.
Using a cotransfection method in
HEK293T cellswith constructs expressing
HA-ubiquitin mutated AR and phospho-
defective AR construct, they reported
reduced ubiquitilation of the phosphor-
defective AR. Subsequent experiments
utilizing the proteosome inhibitor MG132
indicate a dose-dependent inhibition
of the IGF-1-mediated clearance of AR.
Supply of rapamycin did not influence3, August 13, 2009 ª2009 Elsevier Inc. 277
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mechanism of IGF-1 action. The present
study highlights the importance of post-
translational modifications of proteins
harboring CAG repeats in reversing
adverse neurodegenerative effects of
polyQ disorders.
It has been shown previously that
altering testosterone levels by castration
of males (Katsuno et al., 2002) or supply
of leuprorelin (Katsuno et al., 2003), a
luteinizing hormone releasing hormone
(LHRH) analog, which inhibits production
of testosterone by the testis, relieved
adverse symptoms associated with
SBMA in a mouse model, including
nuclear localization of AR and formation
of inclusions. Similarly, Takeyama et al.
(2002) reported that supply of andro-
gen accelerated neuronal degeneration,
nuclear inclusions, and conformational
alterations of the AR in a fruit fly model
overexpressing mutated hAR. Without
underestimating the importance of those
studies, the approaches described here
promote the clearance of the mutant AR
and offer an alternative therapeutic
strategy for SBMA.
IGF-1 has other therapeutic mecha-
nisms in addition to those proposed by
Palazzolo et al. (2009). In a related study
on amyotrophic lateral sclerosis (ALS),
IGF-1, delivered with adeno-associated
virus to themuscle, was shown to prolong
the lifespan and delay disease progres-
sion in mouse models of ALS (Kaspar
et al., 2003). ALS is distinct from SBMA
in the rapid progression of the disease.
However, both are lethal neuromuscular
diseases leading to atrophy of limb and
respiratory muscles and loss of motor278 Neuron 63, August 13, 2009 ª2009 Elseneurons. These studies were reported
seven years ago and therefore progress
to validate this therapeutic treatment in
ALS has moved slowly. Further, the influ-
ence of IGF-1 on the levels of vascular
endothelial growth factor (VEGF) has not
been considered. VEGF has been shown
to be essential for motor neuron survival
and plays an important role in SBMA
(Sopher et al., 2004). IGF-I is an effective
inducer of VEGF secretion and mRNA
expression in some cell types (Kaczmarek
et al., 2008).
In summary, Palazzolo et al. provide
compelling evidence that IGF-1 treatment
results in a dramatic extension of lifespan
and functional recovery of SBMA mice.
Further studies directed at developing a
therapy for SBMA patients with IGF-1 or
compounds with similar mechanism of
action are warranted. Clearly, in light of
this work and prior studies, the mecha-
nism by which IGF-1 blocks muscle
atrophy should be explored as this may
be relevant to other diseases. Finally,
IGF-1 promoted clearance of mutant AR
and this approach may be relevant to a
number of diseases caused by protein
misfolding.
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